Introduction In the early 1980's we observed that neuropeptides can alter the affinity and density of the monoamine agonist and antagonist binding sites in different regions of the CNS, in a receptor subtype specific way [1,2]. This indicated the presence of neuropeptide-monoamine receptor-receptor interactions in the plasma membrane. The molecular mechanisms for
No takes yet. Share an insight, caveat, or question.
Fuxé et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: